To Get Help Now
Click Here
Today's Date:

Johnson & Johnson Reaches Risperdal Agreement

AddThis Social Bookmark Button

J&J has reached a settlement with the U.S. Department of Justice in a misdemeanor criminal charge involving the anti-psychotic drug Risperdal and allegations that the company had been promoting the drug for use in dementia patients, as well as for treatment for mood and anxiety disorders as well as other unapproved uses. Allegations were also made that J&J downplayed the risks associated with the drug.

Yesterday’s filing by the company said that DOJ and a U.S. attorney in Philadelphia are “continuing to pursue both criminal and civil actions. Bloomberg has reported that the company has been involved in ongoing discussions to resolve criminal penalties, but that certain issues “remain open before a settlement can be finalized,” Bloomberg reported.

The company is also in negotiations to resolve civil investigations related to Risperdal and Invega marketing, and are unsure if they will be able to reach a settlement in those cases.

J&J has been notified by the U.S. government that the Justice Department will intervene or join multiple whistleblower lawsuits filed against the Janssen Pharmaceuticals unit of J&J over sales practices of Risperdal. The whistleblower suits are still sealed and have not been made public, Bloomberg reported.

J&J has been sued by 11 states who are seeking Medicaid reimbursement, as well as repayment for other public funds paid on Risperdal prescriptions. disclaimer: This article: Johnson & Johnson Reaches Risperdal Agreement was posted on Wednesday, August 10th, 2011 at 8:14 pm at and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.